Neisseria meningitidis group c capsular polysaccharide diphtheria toxoid conjugate antigen
- Generic Name
- Neisseria meningitidis group c capsular polysaccharide diphtheria toxoid conjugate antigen
- Brand Names
- Menactra
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- 2J57K2523T
- Background
Neisseria meningitidis group c capsular polysaccharide diphtheria toxoid conjugate antigen is an active intramuscular immunization for the prophylaxis of invasive meningococcal disease caused by Neisseria meningitidis serogroup c. The vaccine contains N. meningitis serogroup c capsular polysaccharide antigens that are purified and individually conjugated to diphtheria toxoid protein that are extracted from Corynebacterium diphtheriae grown in another culture.
- Associated Conditions
- Invasive Meningococcal Infection caused by Neisseria meningitidis serogroup C
- Associated Therapies
- -
Pfs230D1M-EPA/AS01 Vaccine, a Transmission Blocking Vaccine Against Plasmodium Falciparum, in an Age De-Escalation Trial of Children and a Family Compound Trial in Mali
- Conditions
- Malaria
- Interventions
- Biological: HAVRIXBiological: Pfs230D1M-EPA/AS01Biological: AVAXIMBiological: TYPHIM Vi (Salmonella typhi vaccine)Biological: Menactra
- First Posted Date
- 2019-04-17
- Last Posted Date
- 2024-10-22
- Target Recruit Count
- 1301
- Registration Number
- NCT03917654
- Locations
- 🇲🇱
Mrtc/Usttb, Bamako, Mali
Safety and Immunogenicity of Pfs25M-EPA/AS01 and Pfs230D1M-EPA/AS01 Vaccines, Transmission Blocking Vaccines Against Plasmodium Falciparum, at Full and Fractional Dosing in Adults in Mali
- Conditions
- Malaria
- Interventions
- Biological: Pfs25M-EPABiological: Pfs230D1M-EPABiological: Engerix-BOther: AS01Biological: MenactraOther: Normal SalineDrug: Coartem
- First Posted Date
- 2016-10-24
- Last Posted Date
- 2024-12-10
- Target Recruit Count
- 301
- Registration Number
- NCT02942277
- Locations
- 🇲🇱
Bancoumana Malaria Vaccine Center, Bamako, Mali
Study of the Safety and Immunogenicity of Pfs230D1M-EPA/Alhydrogel and Pfs25M-EPA/Alhydrogel , a Transmission Blocking Vaccine Against Plasmodium Falciparum Malaria, in Adults in the U.S. and Mali
- Conditions
- Malaria
- Interventions
- First Posted Date
- 2015-01-08
- Last Posted Date
- 2019-04-11
- Target Recruit Count
- 538
- Registration Number
- NCT02334462
- Locations
- 🇲🇱
Malaria Research and Training Center, Bamako, Mali
🇺🇸National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.